Xeris Biopharma (XERS) to Release Quarterly Earnings on Thursday

Key Points

• Xeris Biopharma is expected to announce its Q2 2025 earnings on August 7th, with analysts predicting earnings of ($0.03) per share and revenue of $64.58 million.
• Shares of Xeris Biopharma have seen a 1.7% increase, reaching a price of $5.18, with a market cap of $809.27 million.
• Insider Kevin Mcculloch purchased 25,000 shares at an average price of $4.38, increasing his ownership and highlighting insider confidence in the company.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Xeris Biopharma to post earnings of ($0.03) per share and revenue of $64.58 million for the quarter. Xeris Biopharma has set its FY 2025 guidance at EPS.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to analysts' expectations of $57.61 million. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xeris Biopharma Stock Down 1.5%

Shares of NASDAQ:XERS traded down $0.09 during trading on Tuesday, reaching $5.48. 2,483,060 shares of the company's stock traded hands, compared to its average volume of 2,423,602. Xeris Biopharma has a fifty-two week low of $2.10 and a fifty-two week high of $6.07. The company has a 50-day simple moving average of $4.86 and a 200-day simple moving average of $4.51. The firm has a market cap of $856.18 million, a PE ratio of -18.25 and a beta of 0.65.

Analysts Set New Price Targets

Several research analysts have recently issued reports on XERS shares. Oppenheimer upped their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Wall Street Zen downgraded Xeris Biopharma from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Xeris Biopharma has an average rating of "Moderate Buy" and an average price target of $6.25.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin Mcculloch acquired 25,000 shares of the business's stock in a transaction that occurred on Friday, June 13th. The shares were purchased at an average price of $4.38 per share, with a total value of $109,500.00. Following the completion of the transaction, the insider owned 1,708,585 shares in the company, valued at $7,483,602.30. The trade was a 1.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.56% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Xeris Biopharma

A number of hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Xeris Biopharma by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company's stock valued at $461,000 after buying an additional 3,594 shares in the last quarter. Acadian Asset Management LLC bought a new position in Xeris Biopharma during the 1st quarter worth $96,000. Caxton Associates LLP bought a new stake in shares of Xeris Biopharma during the first quarter worth about $170,000. Royal Bank of Canada increased its holdings in Xeris Biopharma by 1,411.2% in the first quarter. Royal Bank of Canada now owns 213,084 shares of the company's stock valued at $1,170,000 after purchasing an additional 198,984 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock valued at $12,726,000 after purchasing an additional 369,420 shares during the last quarter. Institutional investors own 42.75% of the company's stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.